Full-On Reversal of Cardiac Amyloidosis Possible With Antibodies
It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who had their ATTR-related heart failure resolve spontaneously, with cardiac structure and function restored to almost normal. In a small case series, three men (ages 68, 82, and 76) […]
Clinical Challenges: Thromboembolic Risk in Pediatric Cardiomyopathy
Children with cardiomyopathy are one of the highest-risk pediatric groups for developing thrombosis, along with kids with Fontan circulation, systemic-to-pulmonary artery shunt-dependent functionally univentricular circulation, central lines, and Kawasaki disease with coronary aneurysms. Prophylaxis to prevent thromboembolism and associated complications for children with cardiac disease is most commonly done with antiplatelets (such as aspirin and […]
Second-Gen Drug for HCM Emerges, Nipping at Mavacamten’s Heels
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of treatment with aficamten brought resting left ventricular outflow tract (LVOT) gradients down significantly compared with placebo before a 2-week washout period returned gradients to baseline, reported Martin […]